Published in Drug Metab Dispos on April 16, 2007
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res (2009) 1.93
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res (2008) 1.17
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos (2008) 1.00
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos (2008) 0.96
Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther (2010) 0.89
N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk. Drug Metab Dispos (2008) 0.83
Multifunctional peptide-PEG intercalating conjugates: programmatic of gene delivery to the blood-brain barrier. Pharm Res (2010) 0.82
The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res (2011) 0.82
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. Br J Pharmacol (2009) 0.79
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. J Control Release (2015) 0.78
Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells. Pharmaceutics (2011) 0.78
Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS. J Pharm Sci (2015) 0.78
Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis. Drug Metab Dispos (2012) 0.76
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev (2017) 0.75
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther (2003) 1.93
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther (2009) 1.56
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med (2011) 1.42
Drug efflux transporters in the CNS. Adv Drug Deliv Rev (2003) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther (2012) 1.25
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res (2003) 1.17
Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos (2012) 1.13
Distribution kinetics of a micelle-forming block copolymer Pluronic P85. J Control Release (2004) 1.09
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos (2007) 1.06
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos (2008) 1.00
Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res (2005) 0.99
Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab (2006) 0.97
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos (2008) 0.96
Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther (2005) 0.95
Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther (2004) 0.94
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol (2004) 0.92
Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.90
Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos (2012) 0.89
Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci (2006) 0.89
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther (2012) 0.89
Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. Mol Pharm (2012) 0.88
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther (2013) 0.88
Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci (2008) 0.88
pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos (2011) 0.87
Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther (2013) 0.86
OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm (2010) 0.85
Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol Pharm (2007) 0.85
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. J Thorac Oncol (2014) 0.84
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci (2013) 0.84
Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos (2013) 0.84
Utilizing transmembrane convection to enhance solute sampling and delivery by microdialysis: theory and in vitro validation. J Memb Sci (2010) 0.84
Measurement of drug release from microcarriers by microdialysis. J Pharm Sci (2005) 0.84
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer (2012) 0.81
Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci (2006) 0.79
Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm (2010) 0.79
Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development. Drug Metab Dispos (2012) 0.78
Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res (2015) 0.77
Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J Pharm Sci (2009) 0.77
Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat (2006) 0.77
Drug transport studies using quantitative microdialysis. Methods Mol Med (2003) 0.75
Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration. J Cardiovasc Transl Res (2011) 0.75
Separation methods that are capable of revealing blood-brain barrier permeability. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.75